Quick Answer
Immunome Inc. reported Common Stock Shares Outstanding of 113.13 million shares for the year ending 2025.
- Immunome Inc. showed an increase of +75.5% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Immunome Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: 1.12 million shares | Q1 2021: 10.66 million shares | Q2 2021: 11.81 million shares | Q3 2021: 12.09 million shares | Q1 2022: 12.13 million shares | Q2 2022: 12.13 million shares | Q3 2022: 12.13 million shares | Q1 2023: 12.19 million shares | Q2 2023: 12.20 million shares | Q3 2023: 12.20 million shares | Q1 2024: 59.69 million shares | Q2 2024: 60.01 million shares | Q3 2024: 60.42 million shares | Q1 2025: 86.96 million shares | Q2 2025: 87.01 million shares | Q3 2025: 91.71 million shares.
- Over the full 7 years of available data (2019 to 2025), Immunome Inc.'s Common Stock Shares Outstanding has grown by 10,191.7%.
- Historical annual values: Fiscal year 2025: 113.13 million shares | Fiscal year 2024: 64.46 million shares | Fiscal year 2023: 43.25 million shares | Fiscal year 2022: 12.13 million shares | Fiscal year 2021: 12.11 million shares | Fiscal year 2020: 10.63 million shares | Fiscal year 2019: 1.10 million shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: